 Adam Green
Concepts (253)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioma | 18 | 2025 | 351 | 6.450 |
Why?
| | Central Nervous System Neoplasms | 9 | 2025 | 149 | 4.580 |
Why?
| | Brain Neoplasms | 20 | 2025 | 1149 | 4.410 |
Why?
| | Neoplasms | 10 | 2025 | 2454 | 2.070 |
Why?
| | Ependymoma | 4 | 2023 | 161 | 1.650 |
Why?
| | Hydrazines | 3 | 2025 | 34 | 1.580 |
Why?
| | Triazoles | 3 | 2025 | 148 | 1.440 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2025 | 957 | 1.170 |
Why?
| | Child | 34 | 2025 | 20962 | 1.160 |
Why?
| | Glioblastoma | 4 | 2021 | 322 | 1.160 |
Why?
| | Karyopherins | 2 | 2019 | 19 | 1.100 |
Why?
| | Insurance Coverage | 2 | 2019 | 220 | 1.010 |
Why?
| | Brain Stem Neoplasms | 2 | 2017 | 81 | 0.980 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 2 | 2019 | 216 | 0.970 |
Why?
| | Oncogene Proteins, Fusion | 3 | 2021 | 201 | 0.950 |
Why?
| | Protein-Arginine N-Methyltransferases | 1 | 2025 | 27 | 0.920 |
Why?
| | Healthcare Disparities | 2 | 2021 | 580 | 0.890 |
Why?
| | Rhabdomyosarcoma | 2 | 2024 | 64 | 0.880 |
Why?
| | Medical Oncology | 3 | 2024 | 268 | 0.870 |
Why?
| | Cerebellar Neoplasms | 2 | 2023 | 150 | 0.850 |
Why?
| | Antineoplastic Agents | 5 | 2017 | 2045 | 0.840 |
Why?
| | Wilms Tumor | 1 | 2024 | 78 | 0.810 |
Why?
| | Germ-Line Mutation | 2 | 2021 | 140 | 0.800 |
Why?
| | Radiation | 2 | 2021 | 23 | 0.780 |
Why?
| | raf Kinases | 1 | 2021 | 12 | 0.760 |
Why?
| | Cancer Care Facilities | 1 | 2021 | 32 | 0.720 |
Why?
| | Sarcoma, Ewing | 1 | 2022 | 87 | 0.720 |
Why?
| | Proto-Oncogene Proteins c-cbl | 1 | 2021 | 11 | 0.710 |
Why?
| | Socioeconomic Factors | 6 | 2024 | 1214 | 0.700 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2022 | 70 | 0.700 |
Why?
| | Neoplastic Stem Cells | 1 | 2025 | 378 | 0.700 |
Why?
| | Bone Neoplasms | 1 | 2022 | 229 | 0.660 |
Why?
| | Kidney Neoplasms | 1 | 2024 | 347 | 0.650 |
Why?
| | Meningeal Neoplasms | 1 | 2021 | 94 | 0.650 |
Why?
| | Receptors, Nerve Growth Factor | 1 | 2019 | 17 | 0.650 |
Why?
| | MAP Kinase Signaling System | 1 | 2021 | 314 | 0.650 |
Why?
| | Humans | 51 | 2025 | 129847 | 0.640 |
Why?
| | Positron-Emission Tomography | 1 | 2021 | 282 | 0.630 |
Why?
| | Optic Nerve Neoplasms | 1 | 2019 | 11 | 0.620 |
Why?
| | Optic Chiasm | 1 | 2019 | 18 | 0.620 |
Why?
| | Retinoblastoma | 2 | 2016 | 31 | 0.620 |
Why?
| | Infant | 13 | 2024 | 9018 | 0.620 |
Why?
| | Adolescent | 17 | 2025 | 20451 | 0.620 |
Why?
| | Combined Modality Therapy | 6 | 2021 | 1201 | 0.580 |
Why?
| | Craniopharyngioma | 1 | 2019 | 74 | 0.570 |
Why?
| | Choroid Plexus Neoplasms | 1 | 2017 | 8 | 0.570 |
Why?
| | Li-Fraumeni Syndrome | 1 | 2017 | 13 | 0.570 |
Why?
| | Child, Preschool | 13 | 2025 | 10522 | 0.560 |
Why?
| | Clinical Trials as Topic | 2 | 2020 | 1005 | 0.560 |
Why?
| | Everolimus | 1 | 2017 | 88 | 0.560 |
Why?
| | Pituitary Neoplasms | 1 | 2019 | 180 | 0.540 |
Why?
| | Morpholines | 1 | 2017 | 123 | 0.540 |
Why?
| | Neuroimaging | 1 | 2019 | 279 | 0.520 |
Why?
| | Electric Stimulation Therapy | 1 | 2017 | 77 | 0.510 |
Why?
| | Biomarkers, Tumor | 2 | 2019 | 1161 | 0.510 |
Why?
| | Retinal Neoplasms | 1 | 2016 | 26 | 0.500 |
Why?
| | Microbubbles | 3 | 2024 | 48 | 0.500 |
Why?
| | Prognosis | 7 | 2022 | 3773 | 0.490 |
Why?
| | Carcinoma | 1 | 2017 | 213 | 0.490 |
Why?
| | NF-kappa B | 1 | 2019 | 666 | 0.490 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2017 | 434 | 0.480 |
Why?
| | Blood-Brain Barrier | 3 | 2024 | 132 | 0.470 |
Why?
| | Neutropenia | 1 | 2015 | 137 | 0.460 |
Why?
| | Oxadiazoles | 1 | 2014 | 33 | 0.460 |
Why?
| | Gene Expression Regulation, Neoplastic | 6 | 2025 | 1327 | 0.460 |
Why?
| | Genetic Variation | 1 | 2019 | 937 | 0.460 |
Why?
| | Neoplasm Grading | 3 | 2021 | 283 | 0.450 |
Why?
| | Virilism | 1 | 2014 | 5 | 0.450 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2014 | 113 | 0.450 |
Why?
| | Acrylamides | 1 | 2014 | 57 | 0.450 |
Why?
| | Thiazoles | 1 | 2014 | 118 | 0.440 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2021 | 1560 | 0.440 |
Why?
| | Fever | 1 | 2015 | 298 | 0.430 |
Why?
| | Fathers | 1 | 2014 | 50 | 0.430 |
Why?
| | Young Adult | 10 | 2025 | 12467 | 0.430 |
Why?
| | SEER Program | 3 | 2020 | 202 | 0.430 |
Why?
| | Delayed Diagnosis | 1 | 2014 | 79 | 0.430 |
Why?
| | Rare Diseases | 1 | 2014 | 96 | 0.420 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2014 | 60 | 0.420 |
Why?
| | Adrenocortical Carcinoma | 1 | 2014 | 63 | 0.410 |
Why?
| | Proto-Oncogene Proteins B-raf | 3 | 2021 | 210 | 0.410 |
Why?
| | Histones | 3 | 2024 | 588 | 0.400 |
Why?
| | Female | 22 | 2025 | 68829 | 0.390 |
Why?
| | Male | 22 | 2025 | 63759 | 0.370 |
Why?
| | DNA Copy Number Variations | 2 | 2023 | 167 | 0.370 |
Why?
| | Cell Line, Tumor | 6 | 2025 | 3185 | 0.360 |
Why?
| | Testosterone | 1 | 2014 | 372 | 0.350 |
Why?
| | United States | 9 | 2024 | 13913 | 0.350 |
Why?
| | Infant, Newborn | 6 | 2020 | 5772 | 0.310 |
Why?
| | Drug Screening Assays, Antitumor | 2 | 2021 | 191 | 0.310 |
Why?
| | Social Class | 3 | 2023 | 259 | 0.310 |
Why?
| | Retrospective Studies | 6 | 2024 | 14553 | 0.280 |
Why?
| | Quality Improvement | 1 | 2015 | 1112 | 0.270 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2020 | 431 | 0.260 |
Why?
| | Gene Expression Profiling | 2 | 2024 | 1686 | 0.260 |
Why?
| | Proto-Oncogene Proteins | 2 | 2020 | 634 | 0.260 |
Why?
| | Treatment Outcome | 6 | 2025 | 10241 | 0.260 |
Why?
| | Survival Analysis | 2 | 2020 | 1271 | 0.260 |
Why?
| | Disease Progression | 2 | 2024 | 2628 | 0.260 |
Why?
| | Autophagy | 2 | 2019 | 266 | 0.250 |
Why?
| | Cohort Studies | 4 | 2023 | 5444 | 0.240 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 1708 | 0.240 |
Why?
| | Sonication | 1 | 2024 | 13 | 0.230 |
Why?
| | Maximum Tolerated Dose | 1 | 2025 | 193 | 0.230 |
Why?
| | Prospective Studies | 3 | 2023 | 7158 | 0.230 |
Why?
| | Carcinogenesis | 1 | 2025 | 214 | 0.210 |
Why?
| | Biology | 1 | 2024 | 85 | 0.200 |
Why?
| | Hodgkin Disease | 1 | 2024 | 133 | 0.200 |
Why?
| | Case-Control Studies | 2 | 2023 | 3384 | 0.200 |
Why?
| | Astrocytoma | 1 | 2023 | 115 | 0.200 |
Why?
| | DNA Methylation | 3 | 2023 | 606 | 0.200 |
Why?
| | Teratoma | 1 | 2023 | 103 | 0.190 |
Why?
| | Microglia | 1 | 2024 | 234 | 0.190 |
Why?
| | Magnetic Resonance Imaging | 5 | 2024 | 3397 | 0.190 |
Why?
| | Rhabdoid Tumor | 1 | 2023 | 95 | 0.190 |
Why?
| | Cerebrospinal Fluid | 1 | 2022 | 92 | 0.190 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2021 | 16 | 0.190 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 2016 | 0.190 |
Why?
| | Gene Ontology | 1 | 2021 | 49 | 0.180 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 66 | 0.180 |
Why?
| | Cause of Death | 1 | 2023 | 395 | 0.180 |
Why?
| | Medulloblastoma | 1 | 2023 | 191 | 0.180 |
Why?
| | Hematologic Neoplasms | 1 | 2023 | 141 | 0.180 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2021 | 39 | 0.180 |
Why?
| | Epigenesis, Genetic | 2 | 2023 | 615 | 0.180 |
Why?
| | Gene Amplification | 1 | 2021 | 103 | 0.180 |
Why?
| | Registries | 3 | 2024 | 1903 | 0.180 |
Why?
| | Infusions, Intra-Arterial | 1 | 2021 | 53 | 0.180 |
Why?
| | Mice | 6 | 2025 | 16983 | 0.170 |
Why?
| | Geography | 1 | 2021 | 189 | 0.170 |
Why?
| | Leukocytes | 1 | 2022 | 306 | 0.170 |
Why?
| | Social Determinants of Health | 1 | 2024 | 226 | 0.170 |
Why?
| | Benzamides | 2 | 2019 | 203 | 0.170 |
Why?
| | Mutation | 4 | 2024 | 3706 | 0.170 |
Why?
| | Cell Survival | 3 | 2019 | 1086 | 0.170 |
Why?
| | Cyclophosphamide | 1 | 2021 | 234 | 0.170 |
Why?
| | Recurrence | 1 | 2023 | 1013 | 0.170 |
Why?
| | Transcriptional Elongation Factors | 1 | 2020 | 36 | 0.160 |
Why?
| | Neoplasms, Neuroepithelial | 1 | 2019 | 17 | 0.160 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 279 | 0.160 |
Why?
| | Pedigree | 1 | 2021 | 483 | 0.160 |
Why?
| | Animals | 7 | 2025 | 35409 | 0.160 |
Why?
| | Eye Enucleation | 2 | 2016 | 11 | 0.160 |
Why?
| | Immunophenotyping | 1 | 2021 | 310 | 0.160 |
Why?
| | Protein Domains | 1 | 2021 | 254 | 0.160 |
Why?
| | Anemia, Sickle Cell | 1 | 2023 | 253 | 0.160 |
Why?
| | Cell Proliferation | 2 | 2025 | 2378 | 0.160 |
Why?
| | Age Distribution | 1 | 2020 | 372 | 0.160 |
Why?
| | Sex Distribution | 1 | 2020 | 359 | 0.160 |
Why?
| | Sirolimus | 1 | 2021 | 270 | 0.150 |
Why?
| | Cell Differentiation | 2 | 2017 | 1900 | 0.150 |
Why?
| | Influenza Vaccines | 1 | 2023 | 533 | 0.150 |
Why?
| | Tomography, X-Ray Computed | 2 | 2019 | 2511 | 0.150 |
Why?
| | Tumor Microenvironment | 1 | 2022 | 627 | 0.150 |
Why?
| | Cognitive Dysfunction | 1 | 2023 | 347 | 0.150 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2020 | 399 | 0.140 |
Why?
| | Pyrimidines | 2 | 2019 | 458 | 0.140 |
Why?
| | Genes, p53 | 1 | 2017 | 70 | 0.140 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2017 | 62 | 0.140 |
Why?
| | Transfection | 1 | 2019 | 918 | 0.140 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2017 | 118 | 0.140 |
Why?
| | Mortality | 1 | 2019 | 308 | 0.140 |
Why?
| | Computer Simulation | 1 | 2021 | 941 | 0.130 |
Why?
| | Chloroquine | 1 | 2017 | 51 | 0.130 |
Why?
| | Macrophages | 1 | 2024 | 1489 | 0.130 |
Why?
| | Inflammation | 2 | 2024 | 2748 | 0.130 |
Why?
| | Immunotherapy | 1 | 2021 | 596 | 0.130 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 486 | 0.130 |
Why?
| | Radiotherapy | 1 | 2017 | 185 | 0.130 |
Why?
| | Phenotype | 1 | 2024 | 3062 | 0.120 |
Why?
| | Transcriptome | 1 | 2021 | 875 | 0.120 |
Why?
| | Cell Culture Techniques | 1 | 2017 | 349 | 0.120 |
Why?
| | Macaca fascicularis | 1 | 2014 | 63 | 0.120 |
Why?
| | Cell Cycle | 1 | 2017 | 583 | 0.110 |
Why?
| | Stroke | 1 | 2023 | 1072 | 0.110 |
Why?
| | Adrenalectomy | 1 | 2014 | 66 | 0.110 |
Why?
| | Mutism | 1 | 2014 | 5 | 0.110 |
Why?
| | Cell Cycle Checkpoints | 1 | 2014 | 96 | 0.110 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2021 | 596 | 0.110 |
Why?
| | Administration, Cutaneous | 1 | 2014 | 124 | 0.110 |
Why?
| | Insurance, Health | 1 | 2016 | 269 | 0.110 |
Why?
| | Indoles | 1 | 2017 | 387 | 0.110 |
Why?
| | Chemoradiotherapy | 1 | 2015 | 208 | 0.110 |
Why?
| | Infratentorial Neoplasms | 1 | 2014 | 55 | 0.100 |
Why?
| | Phosphorylation | 1 | 2017 | 1716 | 0.100 |
Why?
| | Diagnostic Errors | 1 | 2014 | 162 | 0.100 |
Why?
| | Sulfonamides | 1 | 2017 | 497 | 0.100 |
Why?
| | Risk Factors | 2 | 2017 | 9801 | 0.100 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2017 | 753 | 0.090 |
Why?
| | Molecular Targeted Therapy | 1 | 2015 | 391 | 0.090 |
Why?
| | Hydrocortisone | 1 | 2014 | 306 | 0.090 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2014 | 808 | 0.090 |
Why?
| | Dexamethasone | 1 | 2014 | 352 | 0.090 |
Why?
| | Epigenomics | 2 | 2023 | 110 | 0.090 |
Why?
| | Drug Delivery Systems | 2 | 2024 | 337 | 0.090 |
Why?
| | Weight Gain | 1 | 2014 | 510 | 0.090 |
Why?
| | Brain | 4 | 2024 | 2677 | 0.080 |
Why?
| | Follow-Up Studies | 2 | 2019 | 4896 | 0.080 |
Why?
| | Rats, Sprague-Dawley | 1 | 2014 | 2403 | 0.080 |
Why?
| | Patient Education as Topic | 1 | 2014 | 743 | 0.080 |
Why?
| | Electronic Health Records | 1 | 2015 | 979 | 0.070 |
Why?
| | Longitudinal Studies | 1 | 2014 | 2724 | 0.070 |
Why?
| | Adult | 4 | 2024 | 35634 | 0.060 |
Why?
| | Apoptosis | 1 | 2014 | 2489 | 0.060 |
Why?
| | Ultrasonic Waves | 1 | 2024 | 5 | 0.060 |
Why?
| | Receptors, CCR1 | 1 | 2024 | 4 | 0.060 |
Why?
| | Time Factors | 1 | 2015 | 6550 | 0.060 |
Why?
| | Receptors, CCR5 | 1 | 2024 | 57 | 0.060 |
Why?
| | Mice, Inbred C57BL | 2 | 2024 | 5468 | 0.050 |
Why?
| | Histology | 1 | 2023 | 4 | 0.050 |
Why?
| | Chromosomes, Human, Pair 10 | 1 | 2023 | 18 | 0.050 |
Why?
| | Myeloid Cells | 1 | 2024 | 142 | 0.050 |
Why?
| | Particle Size | 1 | 2024 | 355 | 0.050 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2023 | 69 | 0.050 |
Why?
| | Research Personnel | 1 | 2024 | 156 | 0.050 |
Why?
| | Career Choice | 1 | 2024 | 206 | 0.050 |
Why?
| | Mitosis | 1 | 2023 | 180 | 0.050 |
Why?
| | Contrast Media | 1 | 2024 | 394 | 0.050 |
Why?
| | Cerebellum | 1 | 2023 | 218 | 0.050 |
Why?
| | Surveys and Questionnaires | 2 | 2024 | 5437 | 0.050 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2021 | 59 | 0.050 |
Why?
| | Chromosome Deletion | 1 | 2021 | 103 | 0.050 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2021 | 42 | 0.050 |
Why?
| | Immunization | 1 | 2023 | 411 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2023 | 426 | 0.040 |
Why?
| | Neoplasm Staging | 1 | 2024 | 1282 | 0.040 |
Why?
| | Gene Rearrangement | 1 | 2021 | 148 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2021 | 483 | 0.040 |
Why?
| | Dendritic Cells | 1 | 2023 | 481 | 0.040 |
Why?
| | Administration, Oral | 1 | 2021 | 787 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2021 | 851 | 0.040 |
Why?
| | Genome, Human | 1 | 2021 | 393 | 0.040 |
Why?
| | Tumor Suppressor Proteins | 1 | 2021 | 311 | 0.040 |
Why?
| | Aminopyridines | 1 | 2019 | 98 | 0.040 |
Why?
| | Health Personnel | 1 | 2024 | 658 | 0.040 |
Why?
| | RNA-Binding Proteins | 1 | 2021 | 388 | 0.040 |
Why?
| | Blotting, Western | 1 | 2019 | 1204 | 0.030 |
Why?
| | Pediatrics | 1 | 2024 | 1074 | 0.030 |
Why?
| | Chromatin | 1 | 2020 | 478 | 0.030 |
Why?
| | Pandemics | 1 | 2024 | 1500 | 0.030 |
Why?
| | Drug Synergism | 1 | 2017 | 370 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2019 | 1160 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2021 | 886 | 0.030 |
Why?
| | Transcription Factors | 1 | 2023 | 1645 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2021 | 1416 | 0.030 |
Why?
| | Vaccination | 1 | 2023 | 1348 | 0.030 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2023 | 1284 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2024 | 4077 | 0.030 |
Why?
| | Health Status Disparities | 1 | 2015 | 256 | 0.030 |
Why?
| | Survival Rate | 1 | 2015 | 1872 | 0.020 |
Why?
| | Middle Aged | 2 | 2021 | 31177 | 0.020 |
Why?
| | Signal Transduction | 1 | 2021 | 4935 | 0.020 |
Why?
| | Aged | 1 | 2021 | 22107 | 0.010 |
Why?
|
|
Green's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|